China's Basic Medical Insurance Data: Three Key Trends and Ecosystem Implications
The 2022 National Medical Security Industry Development Statistical Bulletin, along with the Basic Medical Insurance operation data for Q1 to
Policy Push for Long-Term Huiminbao: The Impact on Innovative Medicine
In early January, the National Administration of Financial Regulation (NAFR) issued a draft titled "Notice on Promoting the Smooth
Closing the Affordability Gap: Can China’s Commercial Health Insurance Deliver?
At the end of 2021, individual out-of-pocket (OOP) spending in China constituted 27.7% of total healthcare expenditure (THE), soaring
China Market Access Pathways for Innovative Medicines Infographic
Breaking from my usual bi-weekly newsletters, I have a valuable resource for you: an infographic detailing China Market Access Pathways
Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation
Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai
Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance
In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance positioned
Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")
In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)/the
Access Pathway for Innovative Medicines in China: Basic Social Medical Insurance
To understand the access pathways for innovative medicines in China, we have to follow the money.
Three layers in China’
